Review of recent preclinical and clinical research on ligand-targeted liposomes as delivery systems in triple negative breast cancer therapy

References

• Łaniewski P, Ilhan ZE, Herbst-Kralovetz MM. The microbiome and gynaecological cancer development, prevention and therapy. Nat Rev Urol. 2020;17(4):232–250. doi: 10.1038/s41585-020-0286-z.
   PubMed Web of Science ®Google Scholar
• Motallebi M, Bhia M, Rajani HF, et al. Naringenin: a potential flavonoid phytochemical for cancer therapy. Life Sci. 2022;305:120752. doi: 10.1016/j.lfs.2022.120752.
   PubMed Web of Science ®Google Scholar
• Subhan MA, Muzibur Rahman M. Recent development in metallic nanoparticles for breast cancer therapy and diagnosis. Chem Rec. 2022;22(7):e202100331. doi: 10.1002/tcr.202100331.
   PubMed Web of Science ®Google Scholar
• Li JJ, Tsang JY, Tse GM. Tumor microenvironment in breast cancer—updates on therapeutic implications and pathologic assessment. Cancers. 2021;13(16):4233. doi: 10.3390/cancers13164233.
   PubMed Web of Science ®Google Scholar
• Sher G, Salman NA, Khan AQ, et al. Epigenetic and breast cancer therapy: promising diagnostic and therapeutic applications. Semin Cancer Biol. 2022;83:152–165. doi: 10.1016/j.semcancer.2020.08.009.
   PubMed Web of Science ®Google Scholar
• Chang J, Mo L, Song J, et al. A pH-responsive mesoporous silica nanoparticle-based drug delivery system for targeted breast cancer therapy. J Mater Chem B. 2022;10(17):3375–3385. doi: 10.1039/d1tb02828f.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Jiang Z, Wang M, et al. Current understandings and clinical translation of nanomedicines for breast cancer therapy. Adv Drug Deliv Rev. 2022;180:114034. doi: 10.1016/j.addr.2021.114034.
   PubMed Web of Science ®Google Scholar
• Kumar H, Gupta NV, Jain R, et al. A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer. J Adv Res. 2023;54:271–292. doi: 10.1016/J.JARE.2023.02.005.
   PubMed Web of Science ®Google Scholar
• Tarantino P, Corti C, Schmid P, et al. Immunotherapy for early triple negative breast cancer: research agenda for the next decade. NPJ Breast Cancer. 2022;8(1):23. doi: 10.1038/s41523-022-00386-1.
   PubMed Web of Science ®Google Scholar
• Bianchini G, De Angelis C, Licata L, et al. Treatment landscape of triple-negative breast cancer—expanded options, evolving needs. Nat Rev Clin Oncol. 2021;19(2):91–113. doi: 10.1038/s41571-021-00565-2.
   PubMed Web of Science ®Google Scholar
• Zagami P, Carey LA. Triple negative breast cancer: pitfalls and progress. NPJ Breast Cancer. 2022;8(1):95. doi: 10.1038/s41523-022-00468-0.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang H, Merkher Y, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15(1):1–30. doi: 10.1186/s13045-022-01341-0.
   PubMed Web of Science ®Google Scholar
• Liao M, Zhang J, Wang G, et al. Small-molecule drug discovery in triple negative breast cancer: current situation and future directions. J Med Chem. 2021;64(5):2382–2418. doi: 10.1021/acs.jmedchem.0c01180.
   PubMed Web of Science ®Google Scholar
• Jing Z, Du Q, Zhang X, et al. Nanomedicines and nanomaterials for cancer therapy: progress, challenge and perspectives. Chem Eng J. 2022;446:137147. doi: 10.1016/j.cej.2022.137147.
   Web of Science ®Google Scholar
• Li Y, Zheng X, Chu Q. Bio-based nanomaterials for cancer therapy. Nano Today. 2021;38:101134. doi: 10.1016/j.nantod.2021.101134.
   Web of Science ®Google Scholar
• Cheng Z, Li M, Dey R, et al. Nanomaterials for cancer therapy: current progress and perspectives. J Hematol Oncol. 2021;14(1):85. doi: 10.1186/s13045-021-01096-0.
   PubMed Web of Science ®Google Scholar
• Fei W, Zhang M, Fan X, et al. Engineering of bioactive metal sulfide nanomaterials for cancer therapy. doi: 10.1186/s12951-021-00839-y.
   Google Scholar
• Pourmadadi M, Mahdi Eshaghi M, Ostovar S, et al. Innovative nanomaterials for cancer diagnosis, imaging, and therapy: drug delivery applications. J Drug Deliv Sci Technol. 2023;82:104357. doi: 10.1016/j.jddst.2023.104357.
   Web of Science ®Google Scholar
• Alavi M, Mozafari MR, Hamblin MR, et al. Industrial-scale methods for the manufacture of liposomes and nanoliposomes: pharmaceutical, cosmetic, and nutraceutical aspects. Micro Nano Bio Asp. 2022;1:26–35.
   Google Scholar
• Fu S, Chang L, Liu S, et al. Temperature sensitive liposome based cancer nanomedicine enables tumour lymph node immune microenvironment remodelling. Nat Commun. 2023;14(1):1–17. doi: 10.1038/s41467-023-38014-6.
   PubMed Web of Science ®Google Scholar
• Hajimolaali M, Mohammadian H, Torabi A, et al. Application of chloroquine as an endosomal escape enhancing agent: new frontiers for an old drug. Expert Opin Drug Deliv. 2021;18(7):877–889. doi: 10.1080/17425247.2021.1873272.
   PubMed Web of Science ®Google Scholar
• Maghsoudnia N, Edalat M, Hajimolaali M, et al. Liposomal supplements. Liposomes Funct. Foods Nutraceuticals. 2022;:235–278.
   Google Scholar
• Askarizadeh A, Mashreghi M, Mirhadi E, et al. Doxorubicin-loaded liposomes surface engineered with the matrix metalloproteinase-2 cleavable polyethylene glycol conjugate for cancer therapy. Cancer Nanotechnol. 2023;14(1):18. doi: 10.1186/s12645-023-00169-8.
   PubMed Web of Science ®Google Scholar
• Fu F, Wang W, Wu L, et al. Inhalable biomineralized liposomes for cyclic Ca2+-burst-centered endoplasmic reticulum stress enhanced lung cancer ferroptosis therapy. ACS Nano. 2023;17(6):5486–5502. doi: 10.1021/acsnano.2c10830.
   PubMed Web of Science ®Google Scholar
• Gopi S, Balakrishnan P. Liposomes for functional foods and nutraceuticals : from research to application. n.d.
   Google Scholar
• Trapani A, Mandracchia D, Tripodo G, et al. Protection of dopamine towards autoxidation reaction by encapsulation into non-coated- or chitosan- or thiolated chitosan-coated-liposomes. Colloids Surf B Biointerfaces. 2018;170:11–19. doi: 10.1016/j.colsurfb.2018.05.049.
   PubMed Web of Science ®Google Scholar
• Aloisio C, Antimisiaris SG, Longhi MR. Liposomes containing cyclodextrins or meglumine to solubilize and improve the bioavailability of poorly soluble drugs. J Mol Liq. 2017;229:106–113. doi: 10.1016/j.molliq.2016.12.035.
   Web of Science ®Google Scholar
• Ashrafizadeh M, Delfi M, Zarrabi A, et al. Stimuli-responsive liposomal nanoformulations in cancer therapy: pre-clinical & clinical approaches. J Control Release. 2022;351:50–80. doi: 10.1016/j.jconrel.2022.08.001.
   PubMed Web of Science ®Google Scholar
• Li X, Widjaya AS, Liu J, et al. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs. Acta Biomater. 2020;106:301–313. doi: 10.1016/j.actbio.2020.02.013.
   PubMed Web of Science ®Google Scholar
• Moosavian SA, Bianconi V, Pirro M, et al. Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy. Semin Cancer Biol. 2021;69:337–348. doi: 10.1016/j.semcancer.2019.09.025.
   PubMed Web of Science ®Google Scholar
• Li J, Zhou S, Yu J, et al. Low dose shikonin and anthracyclines coloaded liposomes induce robust immunogenetic cell death for synergistic chemo-immunotherapy. J Control Release. 2021;335:306–319. doi: 10.1016/j.jconrel.2021.05.040.
   PubMed Web of Science ®Google Scholar
• Muñoz-Shugulí C, Vidal CP, Cantero-López P, et al. Encapsulation of plant extract compounds using cyclodextrin inclusion complexes, liposomes, electrospinning and their combinations for food purposes. Trends Food Sci. Technol. 2021;108:177–186. doi: 10.1016/j.tifs.2020.12.020.
   Web of Science ®Google Scholar
• Papadia K, Markoutsa E, Antimisiaris SG. How do the physicochemical properties of nanoliposomes affect their interactions with the hCMEC/D3 cellular model of the BBB? Int J Pharm. 2016;509(1–2):431–438. doi: 10.1016/j.ijpharm.2016.06.019.
   PubMedGoogle Scholar
• Meagher RB, Lewis ZA, Ambati S, et al. DectiSomes: C-type lectin receptor-targeted liposomes as pan-antifungal drugs. Adv Drug Deliv Rev. 2023;196:114776. doi: 10.1016/j.addr.2023.114776.
   PubMed Web of Science ®Google Scholar
• Shan H, Sun X, Liu X, et al. One-Step formation of targeted liposomes in a versatile microfluidic mixing device. Small. 2023;19(7):e2205498. doi: 10.1002/smll.202205498.
   PubMed Web of Science ®Google Scholar
• Zhu W, Yu H, Jia M, et al. Multi-targeting liposomal codelivery of cisplatin and rapamycin inhibits pancreatic cancer growth and metastasis through stromal modulation. Int J Pharm. 2023;644:123316. doi: 10.1016/j.ijpharm.2023.123316.
   PubMedGoogle Scholar
• Luiz MT, Dutra JAP, Tofani, et al. Targeted liposomes: a nonviral gene delivery system for cancer therapy. Pharm. 2022;14(4):821. doi: 10.3390/pharmaceutics14040821.
   Google Scholar
• Ismail M, Yang W, Li Y, et al. Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma. Biomaterials. 2022;287:121608. doi: 10.1016/j.biomaterials.2022.121608.
   PubMed Web of Science ®Google Scholar
• Wang S, Chen Y, Guo J, et al. Liposomes for tumor targeted therapy: a review. Int J Mol Sci. 2023;24(3):2643. doi: 10.3390/ijms24032643.
   PubMed Web of Science ®Google Scholar
• Mukherjee A, Bisht B, Dutta S, et al. Current advances in the use of exosomes, liposomes, and bioengineered hybrid nanovesicles in cancer detection and therapy. Acta Pharmacol Sin. 2022;43(11):2759–2776. doi: 10.1038/s41401-022-00902-w.
   PubMed Web of Science ®Google Scholar
• Mojarad-Jabali S, Farshbaf M, Walker PR, et al. An update on actively targeted liposomes in advanced drug delivery to glioma. Int J Pharm. 2021;602:120645. doi: 10.1016/j.ijpharm.2021.120645.
   PubMed Web of Science ®Google Scholar
• Moosavian SA, Kesharwani P, Singh V, et al. Aptamer-functionalized liposomes for targeted cancer therapy. Aptamers Eng Nanocarriers Cancer Ther. 2023;:141–172.
   Google Scholar
• Saraf S, Jain A, Tiwari A, et al. Advances in liposomal drug delivery to cancer: an overview. J Drug Deliv Sci Technol. 2020;56:101549. doi: 10.1016/j.jddst.2020.101549.
   Web of Science ®Google Scholar
• Tenchov R, Bird R, Curtze AE, et al. Lipid nanoparticles from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano. 2021;15(11):16982–17015. doi: 10.1021/acsnano.1c04996.
   PubMed Web of Science ®Google Scholar
• Nel J, Elkhoury K, Velot É, et al. Functionalized liposomes for targeted breast cancer drug delivery. Bioact Mater. 2023;24:401–437. doi: 10.1016/j.bioactmat.2022.12.027.
   PubMed Web of Science ®Google Scholar
• Guimarães D, Cavaco-Paulo A, Nogueira E. Design of liposomes as drug delivery system for therapeutic applications. Int. J. Pharm. 2021;601:120571. doi: 10.1016/j.ijpharm.2021.120571.
   PubMed Web of Science ®Google Scholar
• Jiang L, Zhou S, Zhang X, et al. Mitochondrion-specific dendritic lipopeptide liposomes for targeted sub-cellular delivery. Nat Commun. 2021;12(1):1–12. doi: 10.1038/s41467-021-22594-2.
   PubMed Web of Science ®Google Scholar
• Belfiore L, Saunders DN, Ranson M, et al. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: challenges and opportunities. J Control Release. 2018;277:1–13. doi: 10.1016/j.jconrel.2018.02.040.
   PubMed Web of Science ®Google Scholar
• George TA, Hsu CC, Meeson A, et al. Nanocarrier-based targeted therapies for myocardial infarction. Pharm. 2022;14(5):930. doi: 10.3390/pharmaceutics14050930.
   Google Scholar
• Raza F, Evans L, Motallebi M, et al. Liposome-based diagnostic and therapeutic applications for pancreatic cancer. Acta Biomater. 2023;157:1–23. doi: 10.1016/j.actbio.2022.12.013.
   PubMed Web of Science ®Google Scholar
• Sonju JJ, Dahal A, Singh SS, et al. Peptide-functionalized liposomes as therapeutic and diagnostic tools for cancer treatment. J Control Release. 2021;329:624–644. doi: 10.1016/j.jconrel.2020.09.055.
   PubMed Web of Science ®Google Scholar
• Charkhat Gorgich EA, Kasbiyan H, Shabani R, et al. Smart chlorotoxin-functionalized liposomes for sunitinib targeted delivery into glioblastoma cells. J Drug Deliv Sci Technol. 2022;77:103908. doi: 10.1016/j.jddst.2022.103908.
   Web of Science ®Google Scholar
• Zhang N, Shu G, Qiao E, et al. DNA-Functionalized liposomes in vivo fusion for NIR-II/MRI guided pretargeted ferroptosis therapy of metastatic breast cancer. ACS Appl Mater Interfaces. 2022;14(18):20603–20615. doi: 10.1021/acsami.2c01105.
   PubMed Web of Science ®Google Scholar
• Si Y, Zhang Y, Ngo HG, et al. Targeted liposomal chemotherapies to treat triple-negative breast cancer. Cancers. 2021;13(15):3749. doi: 10.3390/cancers13153749.
   PubMed Web of Science ®Google Scholar
• van der Koog L, Gandek TB, Nagelkerke A. Liposomes and extracellular vesicles as drug delivery systems: a comparison of composition, pharmacokinetics, and functionalization. Adv Healthc Mater. 2022;11:2100639.
   Web of Science ®Google Scholar
• Abbasi H, Rahbar N, Kouchak M, et al. Functionalized liposomes as drug nanocarriers for active targeted cancer therapy: a systematic review. J Liposome Res. 2022;32(2):195–210. doi: 10.1080/08982104.2021.1903035.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Yang Z, Quan X, et al. Tumor polyamines as guest cues attract host-functionalized liposomes for targeting and hunting via a bio-orthogonal supramolecular strategy. Theranostics. 2023;13(2):611–620. doi: 10.7150/thno.80857.
   PubMed Web of Science ®Google Scholar
• Liu Y, Castro Bravo KM, Liu J. Targeted liposomal drug delivery: a nanoscience and biophysical perspective. Nanoscale Horiz. 2021;6(2):78–94. doi: 10.1039/D0NH00605J.
   PubMed Web of Science ®Google Scholar
• Ibrahim M, Abuwatfa WH, Awad NS, et al. Encapsulation, release, and cytotoxicity of doxorubicin loaded in liposomes, micelles, and metal-organic frameworks: a review. Pharm. 2022;14(2):254. doi: 10.3390/pharmaceutics14020254.
   Google Scholar
• Negro R, Mastrogiacomo R, Carrieri L, et al. Encapsulation of MCC950 in liposomes decorated with anti-frizzled 1 improves drug bioavailability and effectiveness in fatty liver disease. ACS Appl Mater Interfaces. 2023;15(28):33322–33334. doi: 10.1021/acsami.3c04206.
   PubMed Web of Science ®Google Scholar
• Palchetti S, Caputo D, Digiacomo L, et al. Protein corona fingerprints of liposomes: New opportunities for targeted drug delivery and early detection in pancreatic cancer. Pharm. 2019;11(1):31. doi: 10.3390/pharmaceutics11010031.
   Google Scholar
• Ma Z, Xiang X, Li S, et al. Targeting hypoxia-inducible factor-1, for cancer treatment: recent advances in developing small-molecule inhibitors from natural compounds. Semin. Cancer Biol. 2022;80:379–390. doi: 10.1016/j.semcancer.2020.09.011.
   PubMed Web of Science ®Google Scholar
• Shah H, Madni A, Khan MM, et al. pH-responsive liposomes of dioleoyl phosphatidylethanolamine and cholesteryl hemisuccinate for the enhanced anticancer efficacy of cisplatin. Pharm. 2022;14(1):129. doi: 10.3390/pharmaceutics14010129.
   Google Scholar
• Rommasi F, Esfandiari N. Liposomal nanomedicine: applications for drug delivery in cancer therapy. Nanoscale Res Lett. 2021;16:1–20.
   PubMed Web of Science ®Google Scholar
• Liu XL, Dong X, Yang SC, et al. Biomimetic liposomal nanoplatinum for targeted cancer chemophototherapy. Adv Sci. 2021;8(8):2003679. doi: 10.1002/advs.202003679.
   Web of Science ®Google Scholar
• Gkionis L, Campbell RA, Aojula H, et al. Manufacturing drug co-loaded liposomal formulations targeting breast cancer: influence of preparative method on liposomes characteristics and in vitro toxicity. Int J Pharm. 2020;590:119926. doi: 10.1016/j.ijpharm.2020.119926.
   PubMedGoogle Scholar
• Peng T, Xu W, Li Q, et al. Pharmaceutical liposomal delivery—specific considerations of innovation and challenges. Biomater Sci. 2022;11(1):62–75. doi: 10.1039/d2bm01252a.
   PubMed Web of Science ®Google Scholar
• Chen C, Zhou Y, Chen C, et al. Quantification of available ligand density on the surface of targeted liposomal nanomedicines at the single-particle level. ACS Nano. 2022;16(4):6886–6897. doi: 10.1021/acsnano.2c02084.
   PubMed Web of Science ®Google Scholar
• Emami F, Duwa R, Banstola A, et al. Dual receptor specific nanoparticles targeting EGFR and PD-L1 for enhanced delivery of docetaxel in cancer therapy. Biomed Pharmacother. 2023;165:115023. doi: 10.1016/j.biopha.2023.115023.
   PubMed Web of Science ®Google Scholar
• Li Y, Cong H, Wang S, et al. Liposomes modified with bio-substances for cancer treatment. Biomater Sci. 2020;8(23):6442–6468. doi: 10.1039/D0BM01531H.
   PubMed Web of Science ®Google Scholar
• Khafoor AA, Karim AS, Sajadi SM. Recent progress in synthesis of nano based liposomal drug delivery systems: a glance to their medicinal applications. Results Surf Interf. 2023;11:100124. doi: 10.1016/j.rsurfi.2023.100124.
   Google Scholar
• Noble GT, Stefanick JF, Ashley JD, et al. Ligand-targeted liposome design: challenges and fundamental considerations. Trends Biotechnol. 2014;32(1):32–45. doi: 10.1016/j.tibtech.2013.09.007.
   PubMed Web of Science ®Google Scholar
• Gierlich P, Mata AI, Donohoe C, et al. Ligand-targeted delivery of photosensitizers for cancer treatment. Mol. 2020;25(22):5317. doi: 10.3390/molecules25225317.
   PubMed Web of Science ®Google Scholar
• Eroğlu İ, İbrahim M. Liposome–ligand conjugates: a review on the current state of art. J. Drug Target. 2020;28(3):225–244. doi: 10.1080/1061186X.2019.1648479.
   PubMed Web of Science ®Google Scholar
• Naik H, Sonju JJ, Singh S, et al. Lipidated peptidomimetic ligand-functionalized HER2 targeted liposome as Nano-Carrier designed for doxorubicin delivery in cancer therapy. Pharm. 2021;14(3):221. doi: 10.3390/ph14030221.
   Google Scholar
• Yan W, Leung SSY, To KKW. Updates on the use of liposomes for active tumor targeting in cancer therapy. Nanomedicine. 2019;15(3):303–318. doi: 10.2217/nnm-2019-0308.
   PubMed Web of Science ®Google Scholar
• Mesquita BS, Fens MHAM, Di Maggio A, et al. The impact of nanobody density on the targeting efficiency of PEGylated liposomes. Int J Mol Sci. 2022;23(23):14974. 10.3390/ijms232314974
   PubMed Web of Science ®Google Scholar
• Jiang Z, Guan J, Qian J, et al. Peptide ligand-mediated targeted drug delivery of nanomedicines. Biomater Sci. 2019;7(2):461–471. doi: 10.1039/C8BM01340C.
   PubMed Web of Science ®Google Scholar
• El-Tanani M, Nsairat H, Aljabali AA, et al. Dual-loaded liposomal carriers to combat chemotherapeutic resistance in breast cancer. Expert Opin. Drug Deliv. 2024;21(2):309–324. doi: 10.1080/17425247.2024.2311812.
   PubMedGoogle Scholar
• Shi L, Gu H. Cell membrane-camouflaged liposomes and neopeptide-loaded liposomes with TLR agonist R848 provides a prime and boost strategy for efficient personalized cancer vaccine therapy. Nanomedicine. 2023;48:102648. doi: 10.1016/j.nano.2022.102648.
   PubMed Web of Science ®Google Scholar
• Xu M, Yang Y, Yuan Z. Breast cancer cell membrane camouflaged lipid nanoparticles for tumor-targeted NIR-II phototheranostics. Pharmaceutics. 2022;14(7):1367. doi: 10.3390/pharmaceutics14071367.
   PubMed Web of Science ®Google Scholar
• Jin F, Qi J, Liu D, et al. Cancer-cell-biomimetic upconversion nanoparticles combining chemo-photodynamic therapy and CD73 blockade for metastatic triple-negative breast cancer. J Control Release. 2021;337:90–104. doi: 10.1016/j.jconrel.2021.07.021.
   PubMed Web of Science ®Google Scholar
• Xu CH, Ye PJ, Zhou YC, et al. Cell membrane-camouflaged nanoparticles as drug carriers for cancer therapy. Acta Biomater. 2020;105:1–14. doi: 10.1016/j.actbio.2020.01.036.
   PubMed Web of Science ®Google Scholar
• Zhang R, Wu S, Ding Q, et al. Recent advances in cell membrane-camouflaged nanoparticles for inflammation therapy. Drug Deliv. 2021;28(1):1109–1119. doi: 10.1080/10717544.2021.1934188.
   PubMed Web of Science ®Google Scholar
• Miao Y, Yang Y, Guo L, et al. Cell membrane-camouflaged nanocarriers with biomimetic deformability of erythrocytes for ultralong circulation and enhanced cancer therapy. ACS Nano. 2022;16(4):6527–6540. doi: 10.1021/acsnano.2c00893.
   PubMed Web of Science ®Google Scholar
• Zhao YZ, Shen BX, Li XZ, et al. Tumor cellular membrane camouflaged liposomes as a non-invasive vehicle for genes: specific targeting toward homologous gliomas and traversing the blood–brain barrier. Nanoscale. 2020;12(28):15473–15494. doi: 10.1039/d0nr04212a.
   PubMed Web of Science ®Google Scholar
• Dhas N, García MC, Kudarha R, et al. Advancements in cell membrane camouflaged nanoparticles: a bioinspired platform for cancer therapy. J. Control. Release. 2022;346:71–97. doi: 10.1016/j.jconrel.2022.04.019.
   PubMed Web of Science ®Google Scholar
• Zhu L, Zhong Y, Wu S, et al. Cell membrane camouflaged biomimetic nanoparticles: Focusing on tumor theranostics. Mater Today Bio. 2022;14:100228. doi: 10.1016/j.mtbio.2022.100228.
   PubMedGoogle Scholar
• Khan N, Dhritlahre RK, Saneja A, et al. Recent advances in dual-ligand targeted nanocarriers for cancer therapy. Drug Discov. Today. 2022;27(8):2288–2299., doi: 10.1016/j.drudis.2022.04.011.
   PubMed Web of Science ®Google Scholar
• Marqués-Gallego P, De Kroon AIPM. Ligation strategies for targeting liposomal nanocarriers. Biomed Res. Int. 2014;2014:1–12. doi: 10.1155/2014/129458.
   Web of Science ®Google Scholar
• Riaz MK, Riaz MA, Zhang X, et al. Surface functionalization and targeting strategies of liposomes in solid tumor therapy: a review. Int J Mol Sci. 2018;19(1):195. doi: 10.3390/ijms19010195.
   PubMed Web of Science ®Google Scholar
• Li J, Tan T, Zhao L, et al. Recent advancements in liposome-targeting strategies for the treatment of gliomas: a systematic review. ACS Appl Bio Mater. 2020;3(9):5500–5528. doi: 10.1021/acsabm.0c00705.
   PubMedGoogle Scholar
• Almeida B, Nag OK, Rogers KE, et al. Recent progress in bioconjugation strategies for liposome-mediated drug delivery. Mol. 2020;25(23):5672. doi: 10.3390/molecules25235672.
   PubMed Web of Science ®Google Scholar
• Kumari L, Mishra L, Patel P, et al. Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer. J. Drug Target. 2023;31(9):889–907. doi: 10.1080/1061186X.2023.2245579.
   PubMed Web of Science ®Google Scholar
• Sun X, Tang H, Chen Y, et al. Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer. Nat Cancer. 2023;4(5):716–733. doi: 10.1038/s43018-023-00535-w.
   PubMedGoogle Scholar
• Barzaman K, Karami J, Zarei Z, et al. Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol. 2020;84:106535. doi: 10.1016/j.intimp.2020.106535.
   PubMed Web of Science ®Google Scholar
• Rej RK, Thomas JE, Acharyya RK, et al. Targeting the estrogen receptor for the treatment of breast cancer: recent advances and challenges. J Med Chem. 2023;66(13):8339–8381. doi: 10.1021/acs.jmedchem.3c00136.
   PubMed Web of Science ®Google Scholar
• Mercogliano MF, Bruni S, Mauro FL, et al. Emerging targeted therapies for HER2-Positive breast cancer. Cancers (Basel). 2023;15(7):1987. doi: 10.3390/cancers15071987.
   PubMed Web of Science ®Google Scholar
• Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2022;22(2):101–126. doi: 10.1038/s41573-022-00579-0.
   PubMed Web of Science ®Google Scholar
• Si Y, Chen K, Ngo HG, et al. Targeted EV to deliver chemotherapy to treat triple-negative breast cancers. Pharm. 2022;14(1):146. doi: 10.3390/pharmaceutics14010146.
   Google Scholar
• Agostinetto E, Gligorov J, Piccart M. Systemic therapy for early-stage breast cancer: learning from the past to build the future. Nat Rev Clin Oncol. 2022;19(12):763–774. doi: 10.1038/s41571-022-00687-1.
   PubMed Web of Science ®Google Scholar
• Egebe IA, Singh KK. Nanoparticle-Based therapeutics for triple negative breast cancer. Drug Ther. Dev. Triple Negat. Breast Cancer. 2023;:249–272.
   Google Scholar
• Marra A, Trapani D, Viale G, et al. Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. NPJ Breast Cancer. 2020;6(1):54. doi: 10.1038/s41523-020-00197-2.
   PubMed Web of Science ®Google Scholar
• da Silva JL, Cardoso Nunes NC, Izetti P, et al. Triple negative breast cancer: a thorough review of biomarkers. Crit. Rev. Oncol. Hematol. 2020;145:102855. doi: 10.1016/j.critrevonc.2019.102855.
   PubMed Web of Science ®Google Scholar
• Azari M, Bahreini F, Uversky VN, et al. Current therapeutic approaches and promising perspectives of using bioengineered peptides in fighting chemoresistance in triple-negative breast cancer. Biochem Pharmacol. 2023;210:115459. doi: 10.1016/j.bcp.2023.115459.
   PubMed Web of Science ®Google Scholar
• Duffy C, Sorolla A, Wang E, et al. Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer. NPJ Precis Oncol. 2020;4:1–16.
   PubMed Web of Science ®Google Scholar
• Coussy F, Lavigne M, de Koning L, et al. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts. Theranostics. 2020;10(4):1531–1543. doi: 10.7150/thno.36182.
   PubMed Web of Science ®Google Scholar
• Wu HT, Lin J, Liu YE, et al. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway. Phytomedicine. 2021;81:153437. doi: 10.1016/j.phymed.2020.153437.
   PubMed Web of Science ®Google Scholar
• Kaul K, Misri S, Ramaswamy B, et al. Contribution of the tumor and obese microenvironment to triple negative breast cancer. Cancer Lett. 2021;509:115–120. doi: 10.1016/j.canlet.2021.03.024.
   PubMed Web of Science ®Google Scholar
• Linares RL, Benítez JGS, Reynoso MO, et al. Modulation of the leptin receptors expression in breast cancer cell lines exposed to leptin and tamoxifen. Sci Rep. 2019;9(1):1–9. doi: 10.1038/s41598-019-55674-x.
   PubMedGoogle Scholar
• Duarte-Sanmiguel S, Salazar-Puerta AI, Panic A, et al. ICAM-1-decorated extracellular vesicles loaded with miR-146a and Glut1 drive immunomodulation and hinder tumor progression in a murine model of breast cancer. Biomater Sci. 2023;11(20):6834–6847. doi: 10.1039/D3BM00573A.
   PubMed Web of Science ®Google Scholar
• Li D, Hemati H, Park Y, et al. ICAM-1-suPAR-CD11b axis is a novel therapeutic target for metastatic triple-negative breast cancer. Cancers. 2023;15(10):2734. doi: 10.3390/cancers15102734.
   PubMed Web of Science ®Google Scholar
• Chen X, Feng L, Huang Y, et al. Mechanisms and strategies to overcome PD-1/PD-L1 blockade resistance in triple-negative breast cancer. Cancers. 2022;15(1):104. doi: 10.3390/cancers15010104.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Yang Y, Yang R, et al. Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer. Oncogene. 2021;40(31):4992–5001. doi: 10.1038/s41388-021-01896-1.
   PubMed Web of Science ®Google Scholar
• Shamis SAK, McMillan DC, Edwards J. The relationship between hypoxia-inducible factor 1α (HIF-1α) and patient survival in breast cancer: Systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;159:103231. doi: 10.1016/j.critrevonc.2021.103231.
   PubMed Web of Science ®Google Scholar
• Xiang L, Semenza GL. Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy. Adv Cancer Res. 2019;141:175–212. doi: 10.1016/bs.acr.2018.11.001.
   PubMed Web of Science ®Google Scholar
• Ma W, Yang Y, Zhu J, et al. Biomimetic Nanoerythrosome-Coated aptamer–DNA tetrahedron/maytansine conjugates: pH-responsive and targeted cytotoxicity for HER2-positive breast cancer. Adv. Mater. 2022;34:2109609.
   Web of Science ®Google Scholar
• Wu Q, You L, Nepovimova E, et al. Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. J Hematol Oncol. 2022;15(1):77. doi: 10.1186/s13045-022-01292-6.
   PubMed Web of Science ®Google Scholar
• Malavia, N., Kuche, K., Ghadi, R., Jain, S., 2021. A bird’s eye view of the advanced approaches and strategies for overshadowing triple negative breast cancer. J Control Release 330, 72–100. doi: 10.1016/j.jconrel.2020.12.012.
   Google Scholar
• Greer YE, Gilbert SF, Gril B, et al. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer. Breast Cancer Res. 2019;21(1):1–17. doi: 10.1186/s13058-019-1116-1.
   PubMedGoogle Scholar
• Liu L, Wang Y, Miao L, et al. Combination immunotherapy of MUC1 mRNA nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer. Mol. Ther. 2018;26(1):45–55. doi: 10.1016/j.ymthe.2017.10.020.
   PubMed Web of Science ®Google Scholar
• Yamashita N, Fushimi A, Morimoto Y, et al. Targeting MUC1-C suppresses chronic activation of cytosolic nucleotide receptors and STING in triple-negative breast cancer. Cancers. 2022;14(11):2580. doi: 10.3390/cancers14112580.
   PubMed Web of Science ®Google Scholar
• Zhang S, Chen X, Wu C, et al. Novel sphingosine kinase 1 inhibitor suppresses growth of solid tumor and inhibits the lung metastasis of triple-negative breast cancer. J Med Chem. 2022;65(11):7697–7716. doi: 10.1021/acs.jmedchem.2c00040.
   PubMed Web of Science ®Google Scholar
• Gu H, Shi R, Xu C, et al. EGFR-Targeted liposomes combined with ginsenoside Rh2 inhibit triple-negative breast cancer growth and metastasis. Bioconjugate Chem. 2023;34(6):1157–1165. doi: 10.1021/acs.bioconjchem.3c00207.
   PubMed Web of Science ®Google Scholar
• Ren H, He Y, Liang J, et al. Role of liposome size, surface charge, and PEGylation on rheumatoid arthritis targeting therapy. ACS Appl Mater Interfaces. 2019;11(22):20304–20315. doi: 10.1021/acsami.8b22693.
   PubMed Web of Science ®Google Scholar
• Makwana V, Karanjia J, Haselhorst T, et al. Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization. Int J Pharm. 2021;593:120117. doi: 10.1016/j.ijpharm.2020.120117.
   PubMedGoogle Scholar
• Chaudhuri A, Kumar DN, Shaik RA, et al. Lipid-Based nanoparticles as a pivotal delivery approach in triple negative breast cancer (TNBC) therapy. IJMS. 2022;23(17):10068. doi: 10.3390/ijms231710068.
   Google Scholar
• Wang J, Zhu M, Nie G. Biomembrane-based nanostructures for cancer targeting and therapy: from synthetic liposomes to natural biomembranes and membrane-vesicles. Adv Drug Deliv Rev. 2021;178:113974. doi: 10.1016/j.addr.2021.113974.
   PubMed Web of Science ®Google Scholar
• Takata H, Shimizu T, Yamade R, et al. Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route. J Control Release. 2023;360:285–292. doi: 10.1016/j.jconrel.2023.06.027.
   PubMed Web of Science ®Google Scholar
• Wang H, Lin S, Wu X, et al. Interplay between liposomes and IgM: principles, challenges, and opportunities. Adv. Sci. 2023;10(20):2301777. doi: 10.1002/advs.202301777.
   Web of Science ®Google Scholar
• Parveen N, Abourehab MAS, Shukla R, et al. Immunoliposomes as an emerging nanocarrier for breast cancer therapy. Eur Polym J. 2023;184:111781. doi: 10.1016/j.eurpolymj.2022.111781.
   Web of Science ®Google Scholar
• Kasenda B, König D, Manni M, et al. Targeting immunoliposomes to EGFR-positive glioblastoma. ESMO Open. 2022;7(1):100365. doi: 10.1016/j.esmoop.2021.100365.
   PubMed Web of Science ®Google Scholar
• Nguyen VD, Min HK, Kim CS, et al. Folate receptor-targeted liposomal nanocomplex for effective synergistic photothermal-chemotherapy of breast cancer in vivo. Colloids Surf B Biointerfaces. 2019;173:539–548. doi: 10.1016/j.colsurfb.2018.10.013.
   PubMed Web of Science ®Google Scholar
• Chang R, Zou Q, Xing R, et al. Peptide-Based supramolecular nanodrugs as a new generation of therapeutic toolboxes against cancer. Adv. Ther. 2019;2:1900048.
   Web of Science ®Google Scholar
• Duro-Castano A, Borrás C, Herranz-Pérez V, et al. Targeting Alzheimer’s disease with multimodal polypeptide-based nanoconjugates. Sci Adv. 2021;7(13) doi: 10.1126/sciadv.abf9180.
   PubMed Web of Science ®Google Scholar
• Zhai B, Chen P, Wang W, et al. An ATF24 peptide-functionalized β-elemene-nanostructured lipid carrier combined with cisplatin for bladder cancer treatment. Cancer Biol Med. 2020;17(3):676–692. doi: 10.20892/j.issn.2095-3941.2020.0454.
   PubMed Web of Science ®Google Scholar
• Guo RC, Zhang XH, Ji L, et al. Recent progress of therapeutic peptide based nanomaterials: from synthesis and self-assembly to cancer treatment. Biomater Sci. 2020;8(22):6175–6189. doi: 10.1039/D0BM01358G.
   PubMed Web of Science ®Google Scholar
• Jash A, Ubeyitogullari A, Rizvi SSH. Liposomes for oral delivery of protein and peptide-based therapeutics: challenges, formulation strategies, and advances. J Mater Chem B. 2021;9(24):4773–4792. doi: 10.1039/D1TB00126D.
   PubMed Web of Science ®Google Scholar
• Zamani P, Teymouri M, Nikpoor AR, et al. Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer. Eur J Cancer. 2020;129:80–96. doi: 10.1016/j.ejca.2020.01.010.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Meng Y, Zhao Y, et al. Toxicological exploration of peptide-based cationic liposomes in siRNA delivery. Colloids Surf B Biointerfaces. 2019;179:66–76. doi: 10.1016/j.colsurfb.2019.03.052.
   PubMed Web of Science ®Google Scholar
• Lo Giudice C, Zhang H, Wu B, et al. Mechanochemical activation of Class-B G-protein-coupled receptor upon peptide-ligand binding. Nano Lett. 2020;20(7):5575–5582. doi: 10.1021/acs.nanolett.0c02333.
   PubMed Web of Science ®Google Scholar
• Newman MR, Benoit DSW. In vivo translation of peptide-targeted drug delivery systems discovered by phage display. Bioconjug Chem. 2018;29(7):2161–2169. doi: 10.1021/acs.bioconjchem.8b00285.
   PubMed Web of Science ®Google Scholar
• Fatima M, Abourehab MAS, Aggarwal G, et al. Advancement of cell-penetrating peptides in combating triple-negative breast cancer. Drug Discov Today. 2022;27(11):103353. doi: 10.1016/j.drudis.2022.103353.
   PubMed Web of Science ®Google Scholar
• Kuang H, Ku SH, Kokkoli E. The design of peptide-amphiphiles as functional ligands for liposomal anticancer drug and gene delivery. Adv Drug Deliv Rev. 2017;110-111:80–101. doi: 10.1016/j.addr.2016.08.005.
   PubMed Web of Science ®Google Scholar
• González-Cruz AO, Hernández-Juárez J, Ramírez-Cabrera MA, et al. Peptide-based drug-delivery systems: a new hope for improving cancer therapy. J Drug Deliv Sci Technol. 2022;72:103362. doi: 10.1016/j.jddst.2022.103362.
   Web of Science ®Google Scholar
• Wang Q, Jiang N, Fu B, et al. Self-assembling peptide-based nanodrug delivery systems. Biomater Sci. 2019;7(12):4888–4911. doi: 10.1039/c9bm01212e.
   PubMed Web of Science ®Google Scholar
• Liu D, Guo P, McCarthy C, et al. Peptide density targets and impedes triple negative breast cancer metastasis. Nat Commun. 2018;9(1):1–11. doi: 10.1038/s41467-018-05035-5.
   PubMedGoogle Scholar
• Liu C, Zhao Z, Gao R, et al. Matrix metalloproteinase-2-responsive surface-Changeable liposomes decorated by multifunctional peptides to overcome the drug resistance of triple-negative breast cancer through enhanced targeting and penetrability. ACS Biomater Sci Eng. 2022;8(7):2979–2994. doi: 10.1021/acsbiomaterials.2c00295.
   PubMed Web of Science ®Google Scholar
• Li S, Xie X, Wang W, et al. Choline phosphate lipid as an intra-crosslinker in liposomes for drug and antibody delivery under guard. Nanoscale. 2022;14(6):2277–2286. doi: 10.1039/d1nr07103c.
   PubMed Web of Science ®Google Scholar
• Chen Z, Kankala RK, Yang Z, et al. Antibody-based drug delivery systems for cancer therapy: mechanisms, challenges, and prospects. Theranostics. 2022;12(8):3719–3746. doi: 10.7150/thno.72594.
   PubMedGoogle Scholar
• Ju Y, Lee WS, Pilkington EH, et al. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine. ACS Nano. 2022;16(8):11769–11780. doi: 10.1021/acsnano.2c04543.
   PubMedGoogle Scholar
• Jin S, Sun Y, Liang X, et al. Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct Target Ther. 2022;7:1–28.
   PubMed Web of Science ®Google Scholar
• Marques AC, Costa PC, Velho S, et al. Lipid nanoparticles functionalized with antibodies for anticancer drug therapy. Pharm. 2023;15(1):216. doi: 10.3390/pharmaceutics15010216.
   Google Scholar
• Bu J, Nair A, Iida M, et al. An avidity-based PD-L1 antagonist using nanoparticle-antibody conjugates for enhanced immunotherapy. Nano Lett. 2020;20(7):4901–4909. doi: 10.1021/acs.nanolett.0c00953.
   PubMed Web of Science ®Google Scholar
• Marques AC, Costa PJ, Velho S, et al. Functionalizing nanoparticles with cancer-targeting antibodies: a comparison of strategies. J Control Release. 2020;320:180–200. doi: 10.1016/j.jconrel.2020.01.035.
   PubMed Web of Science ®Google Scholar
• Juan A, Cimas FJ, Bravo I, et al. An overview of antibody conjugated polymeric nanoparticles for breast cancer therapy. Pharm. 2020;12(9):802. doi: 10.3390/pharmaceutics12090802.
   Google Scholar
• Münter R, Stavnsbjerg C, Christensen E, et al. Unravelling heterogeneities in complement and antibody opsonization of individual liposomes as a function of surface architecture. Small. 2022;18(14):e2106529. doi: 10.1002/smll.202106529.
   PubMed Web of Science ®Google Scholar
• Tao X, Wang X, Liu B, et al. Conjugation of antibodies and aptamers on nanozymes for developing biosensors. Biosens Bioelectron. 2020;168:112537. doi: 10.1016/j.bios.2020.112537.
   PubMed Web of Science ®Google Scholar
• Liao WS, Ho Y, Lin YW, et al. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite. Acta Biomater. 2019;86:395–405. doi: 10.1016/j.actbio.2019.01.025.
   PubMed Web of Science ®Google Scholar
• Marmé F, Schneeweiss A. Targeted therapies in triple-negative breast cancer. Breast Care. 2015;10(3):159–166. doi: 10.1159/000433622.
   PubMed Web of Science ®Google Scholar
• Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol Immunother. 2021;70(3):607–617. doi: 10.1007/s00262-020-02736-z.
   PubMed Web of Science ®Google Scholar
• Emens LA, Adams S, Barrios CH, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021;32(12):1650–1993. doi: 10.1016/j.annonc.2021.05.355.
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Abrial C, Mouret-Reynier MA, et al. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact. Ann Oncol. 2014;25(8):1570–1577. doi: 10.1093/annonc/mdu183.
   PubMed Web of Science ®Google Scholar
• Yin L, Duan JJ, Bian XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61. doi: 10.1186/s13058-020-01296-5.
   PubMed Web of Science ®Google Scholar
• Al-Mahmood S, Sapiezynski J, Garbuzenko OB, et al. Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Deliv Transl Res. 2018;8(5):1483–1507. doi: 10.1007/s13346-018-0551-3.
   PubMed Web of Science ®Google Scholar
• Facca VJ, Cai Z, Ku A, et al. Adjuvant auger electron-emitting radioimmunotherapy with [111In]in-DOTA-Panitumumab in a mouse model of local recurrence and metastatic progression of human triple-negative breast cancer. Mol Pharmaceutics. 2023;20(12):6407–6419. doi: 10.1021/acs.molpharmaceut.3c00780.
   PubMed Web of Science ®Google Scholar
• Carey LA, Loirat D, Punie K, et al. Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis. NPJ Breast Cancer. 2022;8(1):72. doi: 10.1038/s41523-022-00439-5.
   PubMed Web of Science ®Google Scholar
• Olivier T, Prasad V. Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): four design features in the ASCENT trial potentially favored the experimental arm. Transl Oncol. 2022;15(1):101248. doi: 10.1016/j.tranon.2021.101248.
   PubMed Web of Science ®Google Scholar
• Guo P, Yang J, Liu D, et al. Dual complementary liposomes inhibit triple-negative breast tumor progression and metastasis. Sci Adv. 2019;5(3). doi: 10.1126/sciadv.aav5010.
   Web of Science ®Google Scholar
• Paoletti A, Ly B, Cailleau C, et al. Liposomal antagomiR-155-5p restores anti-inflammatory macrophages and improves arthritis in pre-clinical models of rheumatoid arthritis. Arthritis Rheumatol. 2023;76(1):18–31. doi: 10.1002/ART.42665.
   PubMed Web of Science ®Google Scholar
• De Leo V, Milano F, Agostiano A, et al. Recent advancements in polymer/liposome assembly for drug delivery: from surface modifications to hybrid vesicles. Polym. 2021;13(7):1027. doi: 10.3390/polym13071027.
   PubMed Web of Science ®Google Scholar
• Lai WF, Wong WT, Rogach AL. Molecular design of layer-by-layer functionalized liposomes for oral drug delivery. ACS Appl Mater Interfaces. 2020;12(39):43341–43351. doi: 10.1021/acsami.0c13504.
   PubMed Web of Science ®Google Scholar
• Willes KL, McFarland SA, Johnson TE, et al. Modulating and modeling the surface ζ potential of hybrid lipid/polymer nanovesicles: implications for surface modification and drug delivery. ACS Appl Nano Mater. 2022;5(10):13820–13828. doi: 10.1021/acsanm.2c01407.
   Web of Science ®Google Scholar
• Behera A, Padhi S, Nayak AK. Engineered liposomes as drug delivery and imaging agents. Des. Appl. Theranostic Nanomedicines. 2023;75–108.
   Google Scholar
• Cao Y, Dong X, Chen X. Polymer-modified liposomes for drug delivery: from fundamentals to applications. Pharm. 2022;14(4):778. doi: 10.3390/pharmaceutics14040778.
   Google Scholar
• Singh A, Neupane YR, Shafi S, et al. PEGylated liposomes as an emerging therapeutic platform for oral nanomedicine in cancer therapy: in vitro and in vivo assessment. J Mol Liq. 2020;303:112649. doi: 10.1016/j.molliq.2020.112649.
   Web of Science ®Google Scholar
• Ghosh B, Biswas S. Polymeric micelles in cancer therapy: state of the art. J Control Release. 2021;332:127–147. doi: 10.1016/j.jconrel.2021.02.016.
   PubMed Web of Science ®Google Scholar
• Wang S, Cheng K, Chen K, et al. Nanoparticle-based medicines in clinical cancer therapy. Nano Today. 2022;45:101512. doi: 10.1016/j.nantod.2022.101512.
   Web of Science ®Google Scholar
• Aguilera-Garrido A, Molina-Bolívar JA, Gálvez-Ruiz MJ, et al. Mucoadhesive properties of liquid lipid nanocapsules enhanced by hyaluronic acid. J Mol Liq. 2019;296:111965. doi: 10.1016/j.molliq.2019.111965.
   Web of Science ®Google Scholar
• Jana Sougata Jana Subrata Domb AJ, Abraham J. Polysaccharide-based biomaterials : delivery of therapeutics and biomedical applications. R Soc Chem. 2022;13:604.
   Google Scholar
• Maghsoudnia N, Baradaran Eftekhari R, Roshandel M, et al. 2022. Hyaluronic acid in drug delivery. In: Polysaccharide-based biomaterials: delivery of therapeutics and biomedical applications. Royal Society of Chemistry, p. 126.
   Google Scholar
• Liu J, Ye Z, Xiang M, et al. Functional extracellular vesicles engineered with lipid-grafted hyaluronic acid effectively reverse cancer drug resistance. Biomaterials. 2019;223:119475. doi: 10.1016/j.biomaterials.2019.119475.
   PubMed Web of Science ®Google Scholar
• Mahmoudi S, Ghorbani M, Sabzichi M, et al. Targeted hyaluronic acid-based lipid nanoparticle for apigenin delivery to induce Nrf2-dependent apoptosis in lung cancer cells. J Drug Deliv Sci Technol. 2019;49:268–276. doi: 10.1016/j.jddst.2018.11.013.
   Web of Science ®Google Scholar
• Bhattacharya S, Ghosh A, Maiti S, et al. Delivery of thymoquinone through hyaluronic acid-decorated mixed pluronic® nanoparticles to attenuate angiogenesis and metastasis of triple-negative breast cancer. J Control Release. 2020;322:357–374. doi: 10.1016/j.jconrel.2020.03.033.
   PubMed Web of Science ®Google Scholar
• Zhang T, Fu C, Alradwan I, et al. Targeting signaling pathways of hyaluronic acid and integrin receptors by synergistic combination nanocomposites inhibits systemic metastases and primary triple negative breast cancer. Adv Ther. 2021;4:2100022.
   Google Scholar
• Wang X, Song Y, Yu L, et al. Co-delivery of hesperetin and cisplatin via hyaluronic acid-modified liposome for targeted inhibition of aggression and metastasis of triple-negative breast cancer. ACS Appl Mater Interfaces. 2023;15(29):34360–34377. doi: 10.1021/acsami.3c03233.
   PubMed Web of Science ®Google Scholar
• Ding Y, Yang R, Yu W, et al. Chitosan oligosaccharide decorated liposomes combined with TH302 for photodynamic therapy in triple negative breast cancer doi: 10.1186/s12951-021-00891-8.
   Google Scholar
• Dong S, Bi Y, Sun X, et al. Dual-Loaded liposomes tagged with hyaluronic acid have synergistic effects in triple-negative breast cancer. Small. 2022;18(16):2107690. doi: 10.1002/smll.202107690.
   Web of Science ®Google Scholar
• Kar A, Rout SR, Giri L, et al. Aptamer-functionalized nanoparticles for targeted cancer therapy. Aptamers Eng Nanocarriers Cancer Ther. 2023;:191–218.
   Google Scholar
• Wan Q, Zeng Z, Qi J, et al. Aptamer-armed nanostructures improve the chemotherapy outcome of triple-negative breast cancer. Mol Ther. 2022;30(6):2242–2256. doi: 10.1016/j.ymthe.2022.02.004.
   PubMed Web of Science ®Google Scholar
• Lafi Z, Alshaer W, Hatmal MM, et al. Aptamer-functionalized pH-sensitive liposomes for a selective delivery of echinomycin into cancer cells. RSC Adv. 2021;11(47):29164–29177. doi: 10.1039/D1RA05138E.
   PubMed Web of Science ®Google Scholar
• Sheikh A, Md S, Kesharwani P. Aptamer grafted nanoparticle as targeted therapeutic tool for the treatment of breast cancer. Biomed Pharmacother. 2022;146:112530. doi: 10.1016/j.biopha.2021.112530.
   PubMed Web of Science ®Google Scholar
• Sheikh A, Abourehab MAS, Tulbah, et al. Aptamer-grafted, cell membrane-coated dendrimer loaded with doxorubicin as a targeted nanosystem against epithelial cellular adhesion molecule (EpCAM) for triple negative breast cancer therapy. J. Drug Deliv Sci Technol. 2023;86:104745. doi: 10.1016/j.jddst.2023.104745.
   Web of Science ®Google Scholar
• Kim MW, Jeong HY, Kang SJ, et al. Anti-EGF receptor aptamer-guided co-delivery of anti-cancer siRNAs and quantum dots for theranostics of triple-negative breast cancer. Theranostics. 2019;9(3):837–852. doi: 10.7150/thno.30228.
   PubMed Web of Science ®Google Scholar
• Sauvage F, Fattal E, Al-Shaer W, et al. Antitumor activity of nanoliposomes encapsulating the novobiocin analog 6BrCaQ in a triple-negative breast cancer model in mice. Cancer Lett. 2018;432:103–111. doi: 10.1016/j.canlet.2018.06.001.
   PubMed Web of Science ®Google Scholar
• Alshaer W, Hillaireau H, Vergnaud J, et al. Aptamer-guided siRNA-loaded nanomedicines for systemic gene silencing in CD-44 expressing murine triple-negative breast cancer model. J Control Release. 2018;271:98–106. doi: 10.1016/j.jconrel.2017.12.022.
   PubMed Web of Science ®Google Scholar
• Hu H, Yu L, Ding Z, et al. Chemo–immunotherapy for chemo-resistance and metastasis of triple-negative breast cancer by combination of iron-oxide nanoparticles and dual-targeting doxorubicin liposomes. Chinese Chem Lett. 2023;34(10):108592. doi: 10.1016/j.cclet.2023.108592.
   Web of Science ®Google Scholar
• Li X, Zhang Z, Gao F, et al. c-Myc-Targeting PROTAC based on a TNA-DNA bivalent binder for combination therapy of triple-negative breast cancer. J Am Chem Soc. 2023;145(16):9334–9342. doi: 10.1021/jacs.3c02619.
   PubMed Web of Science ®Google Scholar
• Fan Y, Wang Q, Lin G, et al. Combination of using prodrug-modified cationic liposome nanocomplexes and a potentiating strategy via targeted co-delivery of gemcitabine and docetaxel for CD44-overexpressed triple negative breast cancer therapy. Acta Biomater. 2017;62:257–272. doi: 10.1016/j.actbio.2017.08.034.
   PubMed Web of Science ®Google Scholar
• Chen M, Miao Y, Qian K, et al. Detachable liposomes combined immunochemotherapy for enhanced triple-negative breast cancer treatment through reprogramming of tumor-associated macrophages. Nano Lett. 2021;21(14):6031–6041. doi: 10.1021/acs.nanolett.1c01210.
   PubMed Web of Science ®Google Scholar
• Chen M, Wang S, Qi Z, et al. Deuterated colchicine liposomes based on oligomeric hyaluronic acid modification enhance anti-tumor effect and reduce systemic toxicity. Int J Pharm. 2023;632:122578. doi: 10.1016/j.ijpharm.2022.122578.
   PubMedGoogle Scholar
• Pu Y, Zhang H, Peng Y, et al. Dual-targeting liposomes with active recognition of GLUT5 and αvβ3 for triple-negative breast cancer. Eur J Med Chem. 2019;183:111720. doi: 10.1016/j.ejmech.2019.111720.
   PubMed Web of Science ®Google Scholar
• Matusewicz L, Filip-Psurska B, Psurski M, et al. EGFR-targeted immunoliposomes as a selective delivery system of simvastatin, with potential use in treatment of triple-negative breast cancers. Int J Pharm. 2019;569:118605. doi: 10.1016/j.ijpharm.2019.118605.
   PubMed Web of Science ®Google Scholar
• Gharaibeh L, Alshaer W, Wehaibi S, et al. Fabrication of aptamer-guided siRNA loaded lipopolyplexes for gene silencing of notch 1 in MDA-mb-231 triple negative breast cancer cell line. J Drug Deliv Sci Technol. 2021;65:102733. doi: 10.1016/j.jddst.2021.102733.
   Web of Science ®Google Scholar
• Meng L, Ren J, Liu Z, et al. Hyaluronic acid-coated shikonin liposomes for the treatment of triple-negative breast cancer via targeting tumor cells and amplification of oxidative stress. J Drug Deliv Sci Technol. 2022;70:103193. doi: 10.1016/j.jddst.2022.103193.
   Web of Science ®Google Scholar
• Guo P, Yang J, Jia D, et al. ICAM-1-targeted, Lcn2 siRNA-encapsulating liposomes are potent anti-angiogenic agents for triple negative breast cancer. Theranostics. 2016;6(1):1–13. doi: 10.7150/thno.12167.
   PubMed Web of Science ®Google Scholar
• d‘Avanzo N, Torrieri G, Figueiredo P, et al. LinTT1 peptide-functionalized liposomes for targeted breast cancer therapy. Int J Pharm. 2021;597:120346., doi: 10.1016/j.ijpharm.2021.120346.
   PubMed Web of Science ®Google Scholar
• Yue G, Wang C, Liu B, et al. Liposomes co-delivery system of doxorubicin and astragaloside IV co-modified by folate ligand and octa-arginine polypeptide for anti-breast cancer. RSC Adv. 2020;10(20):11573–11581. doi: 10.1039/c9ra09040a.
   PubMed Web of Science ®Google Scholar
• De Vita A, Liverani C, Molinaro R, et al. Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer. Sci Rep. 2021;11(1):1–12. doi: 10.1038/s41598-021-84492-3.
   PubMed Web of Science ®Google Scholar
• Jyotsana N, Zhang Z, Himmel LE, et al. Minimal dosing of leukocyte targeting TRAIL decreases triple-negative breast cancer metastasis following tumor resection. Sci Adv. 2019;5(7):4197–4221. doi: 10.1126/sciadv.aaw4197.
   Web of Science ®Google Scholar
• Zhou F, Feng B, Wang T, et al. Programmed multiresponsive vesicles for enhanced tumor penetration and combination therapy of triple-negative breast cancer. Adv Funct Mater. 2017;27:1606530.
   Web of Science ®Google Scholar
• Chen C, Shen M, Liao H, et al. A paclitaxel and microRNA-124 coloaded stepped cleavable nanosystem against triple negative breast cancer. J Nanobiotechnol. 2021;19(1):1–17. doi: 10.1186/s12951-021-00800-z.
   PubMed Web of Science ®Google Scholar
• Lu G, Qiu Y, Su X. Targeting CXCL12-CXCR4 signaling enhances immune checkpoint blockade therapy against triple negative breast cancer. Eur J Pharm Sci. 2021;157:105606. doi: 10.1016/j.ejps.2020.105606.
   PubMed Web of Science ®Google Scholar
• Xia J, Zhang S, Zhang R, et al. Targeting therapy and tumor microenvironment remodeling of triple-negative breast cancer by ginsenoside Rg3 based liposomes. J Nanobiotechnology. 2022;20(1):414. doi: 10.1186/s12951-022-01623-2.
   PubMed Web of Science ®Google Scholar
• Doddapaneni R, Patel K, Owaid IH, et al. Tumor neovasculature-targeted cationic PEGylated liposomes of gambogic acid for the treatment of triple-negative breast cancer. Drug Deliv. 2015;23(4):1232–1241. doi: 10.3109/10717544.2015.1124472.
   PubMed Web of Science ®Google Scholar
• Chaudhari D, Katari O, Ghadi R, et al. Unfolding the potency of adenosine in targeting triple negative breast cancer via paclitaxel-incorporated pH-responsive stealth liposomes. ACS Biomater Sci Eng. 2022;8(8):3473–3484. doi: 10.1021/acsbiomaterials.2c00594.
   PubMed Web of Science ®Google Scholar
• Cadinoiu AN, Rata DM, Atanase LI, et al. Aptamer-functionalized liposomes as a potential treatment for basal cell carcinoma. Polym. 2019;11(9):1515. doi: 10.3390/polym11091515.
   PubMed Web of Science ®Google Scholar
• Kim M, Lee JS, Kim W, et al. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression. J Control Release. 2022;348:893–910. doi: 10.1016/j.jconrel.2022.06.039.
   PubMed Web of Science ®Google Scholar
• Khodarahmi M, Abbasi H, Kouchak M, et al. Nanoencapsulation of aptamer-functionalized 5-fluorouracil liposomes using alginate/chitosan complex as a novel targeting strategy for colon-specific drug delivery. J Drug Deliv Sci Technol. 2022;71:103299. doi: 10.1016/j.jddst.2022.103299.
   Web of Science ®Google Scholar
• Zhao Y, Xu J, Le VM, et al. EpCAM aptamer-functionalized cationic liposome-based nanoparticles loaded with miR-139-5p for targeted therapy in colorectal cancer. Mol Pharm. 2019;16(11):4696–4710. doi: 10.1021/acs.molpharmaceut.9b00867.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Zhao L, Li K, et al. Aptamer-functionalized nanoplatforms overcoming temozolomide resistance in synergistic chemo/photothermal therapy through alleviating tumor hypoxia. Nano Res. 2023;16(7):9859–9872. doi: 10.1007/s12274-023-5742-7.
   Web of Science ®Google Scholar
• Lamprou E, Mourtas S, Mantzari M, et al. Folic acid—targeted doxorubicin drug delivery system for triple-negative breast cancer treatment. Proc. 2020;78:4.
   Google Scholar
• Mantzari M, Gartziou F, Lambrou E, et al. Novel TNBC-targeted DOX-arsonoliposomes. Proc. 2020;78:17.
   Google Scholar
• Tang B, Peng Y, Yue Q, et al. Design, preparation and evaluation of different branched biotin modified liposomes for targeting breast cancer. Eur J Med Chem. 2020;193:112204. doi: 10.1016/j.ejmech.2020.112204.
   PubMed Web of Science ®Google Scholar
• Kaur N, Popli P, Tiwary N, et al. Small molecules as cancer targeting ligands: shifting the paradigm. J Control Release. 2023;355:417–433. doi: 10.1016/j.jconrel.2023.01.032.
   PubMed Web of Science ®Google Scholar
• Dutt Y, Pandey RP, Dutt M, et al. Liposomes and phytosomes: nanocarrier systems and their applications for the delivery of phytoconstituents. Coord Chem Rev. 2023;491:215251. doi: 10.1016/j.ccr.2023.215251.
   Web of Science ®Google Scholar
• Belfiore L, Saunders DN, Ranson M, et al. N-alkylisatin-loaded liposomes target the urokinase plasminogen activator system in breast cancer. Pharm. 2020;12(7):641. doi: 10.3390/pharmaceutics12070641.
   Google Scholar
• Luo K, Yang L, Yan C, et al. A dual-targeting liposome enhances triple-negative breast cancer chemoimmunotherapy through inducing immunogenic cell death and inhibiting STAT3 activation. Small. 2023;19(40):2302834. doi: 10.1002/smll.202302834.
   Web of Science ®Google Scholar
• Hattab D, Bakhtiar A. Bioengineered siRNA-based nanoplatforms targeting molecular signaling pathways for the treatment of triple negative breast cancer: preclinical and clinical advancements. Pharm. 2020;12(10):929. doi: 10.3390/pharmaceutics12100929.
   Google Scholar
• Ghosh S, Javia A, Shetty S, et al. Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches. J. Control. Release. 2021;337:27–58. doi: 10.1016/j.jconrel.2021.07.014.
   PubMed Web of Science ®Google Scholar
• Haque S, Cook K, Sahay G, et al. RNA-based therapeutics: current developments in targeted molecular therapy of triple-negative breast cancer. Pharm. 2021;13(10):1694. doi: 10.3390/pharmaceutics13101694.
   Google Scholar
• Sahu R, Jha S, Pattanayak SP. Therapeutic silencing of mTOR by systemically administered siRNA-loaded neutral liposomal nanoparticles inhibits DMBA-induced mammary carcinogenesis. Br J Cancer. 2022;127(12):2207–2219. doi: 10.1038/s41416-022-02011-1.
   PubMed Web of Science ®Google Scholar